Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has experienced a decline in its stock price by -1.75 compared to its previous closing price of 137.49. However, the company has seen a fall of -0.54% in its stock price over the last five trading days. prnewswire.com reported 2024-07-01 that PDUFA Target Action Dates in Late December 2024 Highly Selective CRF1 Antagonist is the Potential First New Treatment for CAH in 70 Years SAN DIEGO, July 1, 2024 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its two New Drug Applications (NDA) with Priority Review designations for crinecerfont in the treatment of children, adolescents and adults with classic congenital adrenal hyperplasia (CAH). If approved, crinecerfont would be the first new treatment option for CAH in 70 years and a first-in-class therapy, with a novel approach for the treatment of this rare and serious endocrine disorder.
Is It Worth Investing in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Right Now?
The price-to-earnings ratio for Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is 37.14x, which is above its average ratio. Moreover, the 36-month beta value for NBIX is 0.37. Analysts have varying opinions on the stock, with 8 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NBIX is 98.41M and currently, short sellers hold a 2.27% of that float. On July 04, 2024, NBIX’s average trading volume was 795.07K shares.
NBIX’s Market Performance
NBIX stock saw a decrease of -0.54% in the past week, with a monthly decline of -3.45% and a quarterly a decrease of -1.82%. The volatility ratio for the week is 2.17%, and the volatility levels for the last 30 days are 2.56% for Neurocrine Biosciences, Inc. (NBIX). The simple moving average for the past 20 days is 0.13% for NBIX’s stock, with a 4.92% simple moving average for the past 200 days.
Analysts’ Opinion of NBIX
Many brokerage firms have already submitted their reports for NBIX stocks, with Wells Fargo repeating the rating for NBIX by listing it as a “Overweight.” The predicted price for NBIX in the upcoming period, according to Wells Fargo is $170 based on the research report published on April 24, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see NBIX reach a price target of $127. The rating they have provided for NBIX stocks is “Neutral” according to the report published on December 13th, 2023.
Deutsche Bank gave a rating of “Buy” to NBIX, setting the target price at $136 in the report published on December 12th of the previous year.
NBIX Trading at -1.75% from the 50-Day Moving Average
After a stumble in the market that brought NBIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.95% of loss for the given period.
Volatility was left at 2.56%, however, over the last 30 days, the volatility rate increased by 2.17%, as shares surge +3.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.42% upper at present.
During the last 5 trading sessions, NBIX rose by +1.77%, which changed the moving average for the period of 200-days by +22.93% in comparison to the 20-day moving average, which settled at $135.15. In addition, Neurocrine Biosciences, Inc. saw 2.53% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NBIX starting from Cooke Julie, who sale 10,000 shares at the price of $140.19 back on Jul 01 ’24. After this action, Cooke Julie now owns 18,202 shares of Neurocrine Biosciences, Inc., valued at $1,401,864 using the latest closing price.
Delaet Ingrid, the Chief Regulatory Officer of Neurocrine Biosciences, Inc., sale 272 shares at $138.11 during a trade that took place back on Jul 01 ’24, which means that Delaet Ingrid is holding 7,507 shares at $37,566 based on the most recent closing price.
Stock Fundamentals for NBIX
Current profitability levels for the company are sitting at:
- 0.24 for the present operating margin
- 0.98 for the gross margin
The net margin for Neurocrine Biosciences, Inc. stands at 0.19. The total capital return value is set at 0.17. Equity return is now at value 18.16, with 12.68 for asset returns.
Based on Neurocrine Biosciences, Inc. (NBIX), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at 1.18. The debt to equity ratio resting at 0.23. The interest coverage ratio of the stock is 102.26.
Currently, EBITDA for the company is 416.1 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 7.09. The receivables turnover for the company is 4.4for trailing twelve months and the total asset turnover is 0.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.52.
Conclusion
To wrap up, the performance of Neurocrine Biosciences, Inc. (NBIX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
